Author:
Cheng Leilei,Xu Yuchen,Zhang Shilong
Funder
National Natural Science Foundation of China
Shanghai Shenkang Hospital Development Center
Subject
Cardiology and Cardiovascular Medicine,Oncology
Reference13 articles.
1. The landscape of immunotherapy in advanced NSCLC: driving beyond PD-1/PD-L1 inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, vaccines);De Giglio;Curr Oncol Rep,2021
2. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study;Salem;Lancet Oncol,2018
3. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis;Moslehi;Lancet,2018
4. Moving towards personalized treatments of immune-related adverse events;Esfahani;Nat Rev Clin Oncol,2020
5. Severe vs nonsevere immune checkpoint inhibitor-induced myocarditis: contemporary 1-year outcomes;Itzhaki Ben Zadok;J Am Coll Cardiol CardioOnc,2023